Loading…
Reported covered position: Vice President, Government & Pharmacy Affairs
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
CREATES Act of 2019
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Communication and correspondence in opposition to S. 657, Drug Price Transparency Act (Braun), support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (no introduced legislation to date)
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2019 · first_quarter · Q1
Communication and correspondence related to rising costs of drugs under Medicare and Medicaid, electronic prescribing, prior authorization and electronic prior authorization. Meeting with the Department of Health and Human services on proposal to restrict the use of rebates under Medicare and Medicaid
Communication and correspondence in opposition to S. 657, Drug Price Transparency Act (Braun), support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (no introduced legislation to date)
Source: Senate LDA
Communication and correspondence in opposition to S. 657, Drug Price Transparency Act (Braun), support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (no introduced legislation to date)
A bill to amend title XXVII of the Public Health Service Act to establish requirements with respect to prescription drug benefits.
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Communication and correspondence in opposition to S. 657, Drug Price Transparency Act (Braun), support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (no introduced legislation to date)
Biologic Patent Transparency Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Communication and correspondence in opposition to S. 657, Drug Price Transparency Act (Braun), support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, and dissemination of materials on pharmaceutical information exchange (no introduced legislation to date)
Pharmaceutical Information Exchange Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Pharmaceutical Information Exchange Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Pharmaceutical Information Exchange Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Pharmaceutical Information Exchange Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Pharmaceutical Information Exchange Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Joined other stakeholders in a letter to Reps. Mullin and Blumenauer of support for H.R. 3545 - Overdose Prevention and Patient Safety Act, also sent a letter of support of H.R. 3545 to House Energy and Commerce Committee in support of H.R.3545 , Joined other stakeholders in letter to Senate and House leadership in support of the CREATES Act (H.R.2212 and S. 974) Delivered remarks at FDA Opioid Policy Steering Committee on ways to address the opioid epidemic, dissemination of pharmacoeconomic information,submitted letter to House Energy and Commerce Committee in support of H.R. 2026 Pharmaceutical Information Exchange Act and submitted a letter to AHRQ in response to a request for information regarding patient reported outcomes measures.
Pharmaceutical Information Exchange Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
CREATES Act of 2017
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Joined other stakeholders in a letter to Reps. Mullin and Blumenauer of support for H.R. 3545 - Overdose Prevention and Patient Safety Act, also sent a letter of support of H.R. 3545 to House Energy and Commerce Committee in support of H.R.3545 , Joined other stakeholders in letter to Senate and House leadership in support of the CREATES Act (H.R.2212 and S. 974) Delivered remarks at FDA Opioid Policy Steering Committee on ways to address the opioid epidemic, dissemination of pharmacoeconomic information,submitted letter to House Energy and Commerce Committee in support of H.R. 2026 Pharmaceutical Information Exchange Act and submitted a letter to AHRQ in response to a request for information regarding patient reported outcomes measures.
Every Prescription Conveyed Securely Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted letter to the House Energy and Commerce Committee for the record in support of H.R. 4841 concerning standardizing electronic prior authorization for Medicare. Also sent a letter to Rep. Schweikert in support of H.R. 4841. Also sent a letter of support for H.R. 3528 for the House Energy and Commerce Committee record. H.R. 3528 provides for the e-prescribing of prescription drugs for controlled substances under Medicare Part D program.
Every Prescription Conveyed Securely Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted letter to the House Energy and Commerce Committee for the record in support of H.R. 4841 concerning standardizing electronic prior authorization for Medicare. Also sent a letter to Rep. Schweikert in support of H.R. 4841. Also sent a letter of support for H.R. 3528 for the House Energy and Commerce Committee record. H.R. 3528 provides for the e-prescribing of prescription drugs for controlled substances under Medicare Part D program. Participated in discussions on the need to address fraud, waste and abuse in the Medicare Part D program.
Overdose Prevention and Patient Safety Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee.
Overdose Prevention and Patient Safety Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Joined other stakeholders in a letter to Reps. Mullin and Blumenauer of support for H.R. 3545 - Overdose Prevention and Patient Safety Act, also sent a letter of support of H.R. 3545 to House Energy and Commerce Committee in support of H.R.3545 , Joined other stakeholders in letter to Senate and House leadership in support of the CREATES Act (H.R.2212 and S. 974) Delivered remarks at FDA Opioid Policy Steering Committee on ways to address the opioid epidemic, dissemination of pharmacoeconomic information,submitted letter to House Energy and Commerce Committee in support of H.R. 2026 Pharmaceutical Information Exchange Act and submitted a letter to AHRQ in response to a request for information regarding patient reported outcomes measures.
Overdose Prevention and Patient Safety Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Small Business Disaster Relief Act of 2017
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted comments to CMS on Medicare Advantage and Medicare Part D Rule, joined other stakeholders in letter HHS OIG in support of a safe harbor provision for that would encourage development of value-based contracts for the Medicare and Medicaid populations,submitted comments to CMS on the 2019 draft Call letter and submitted letter to Rep. Schweikert in support of H.R. 4148 concerning standardizing electronic prior authorization for Medicare beneficiaries.
Empowering Pharmacists in the Fight Against Opioid Abuse Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Empowering Pharmacists in the Fight Against Opioid Abuse Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee.
Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted letter to the House Energy and Commerce Committee for the record in support of H.R. 4841 concerning standardizing electronic prior authorization for Medicare. Also sent a letter to Rep. Schweikert in support of H.R. 4841. Also sent a letter of support for H.R. 3528 for the House Energy and Commerce Committee record. H.R. 3528 provides for the e-prescribing of prescription drugs for controlled substances under Medicare Part D program.
Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted letter to the House Energy and Commerce Committee for the record in support of H.R. 4841 concerning standardizing electronic prior authorization for Medicare. Also sent a letter to Rep. Schweikert in support of H.R. 4841. Also sent a letter of support for H.R. 3528 for the House Energy and Commerce Committee record. H.R. 3528 provides for the e-prescribing of prescription drugs for controlled substances under Medicare Part D program. Participated in discussions on the need to address fraud, waste and abuse in the Medicare Part D program.
SUPPORT for Patients and Communities Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Met with HHS officials regarding the Administration Blueprint to Lower Drug Prices. Submitted comments to HHS in response to Blueprint. Communications and correspondence related to suspension of claims under Medicare Part D for a credible allegation of fraud, electronic prescribing, and prior authorization under Medicare Part D contained in HR 6--The Opioid Crisis Response Act of 2018.
SUPPORT for Patients and Communities Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Communications and correspondence related to suspension of claims under Medicare Part D for a credible allegation of fraud, electronic prescribing, and prior authorization under Medicare Part D contained in HR 6--The Opioid Crisis Response Act of 2018. Meeting with the Centers for Medicare and Medicaid Services regarding the medication therapy management program under Medicare Part D.
SUPPORT for Patients and Communities Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Met with HHS officials regarding the Administration Blueprint to Lower Drug Prices. Submitted comments to HHS in response to Blueprint. Communications and correspondence related to suspension of claims under Medicare Part D for a credible allegation of fraud, electronic prescribing, and prior authorization under Medicare Part D contained in HR 6--The Opioid Crisis Response Act of 2018.
SUPPORT for Patients and Communities Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Met with HHS officials regarding the Administration Blueprint to Lower Drug Prices. Submitted comments to HHS in response to Blueprint. Communications and correspondence related to suspension of claims under Medicare Part D for a credible allegation of fraud, electronic prescribing, and prior authorization under Medicare Part D contained in HR 6--The Opioid Crisis Response Act of 2018.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Joined other stakeholders in a letter to Reps. Mullin and Blumenauer of support for H.R. 3545 - Overdose Prevention and Patient Safety Act, also sent a letter of support of H.R. 3545 to House Energy and Commerce Committee in support of H.R.3545 , Joined other stakeholders in letter to Senate and House leadership in support of the CREATES Act (H.R.2212 and S. 974) Delivered remarks at FDA Opioid Policy Steering Committee on ways to address the opioid epidemic, dissemination of pharmacoeconomic information,submitted letter to House Energy and Commerce Committee in support of H.R. 2026 Pharmaceutical Information Exchange Act and submitted a letter to AHRQ in response to a request for information regarding patient reported outcomes measures.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Pharmaceutical Information Exchange Act
Client: ACADEMY OF MANAGED CARE PHARMACY · Firm: ACADEMY OF MANAGED CARE PHARMACY
Joint letter with other pharmacy associations submitted for the record in the House Energy and Commerce committee hearing on opioids in support of pharmacists being eligible for DATA waivers to provide Medication Assisted Therapy, Comments submitted to HHS Notice of Benefit and payment parameters for 2019;Comments submitted to FDA on direct to consumer advertising, Comments submitted to FDA on potential areas of focus for the opioid policy steering committee, comments submitted to the FTC on solutions and strategies to improve generic competition in the marketplace, comments submitted in response to a request for information from the House of Representatives Diabetes Caucus for information on value based contracting, dissemination of pharmaeconomic information, and H.R. 2026 Pharmaceutical Information Exchange Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2018 · fourth_quarter · Q4
Communications and correspondence related to suspension of claims under Medicare Part D for a credible allegation of fraud, electronic prescribing, and prior authorization under Medicare Part D contained in HR 6--The Opioid Crisis Response Act of 2018. Meeting with the Centers for Medicare and Medicaid Services regarding the medication therapy management program under Medicare Part D.
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2018 · third_quarter · 3A
Met with HHS officials regarding the Administration Blueprint to Lower Drug Prices. Submitted comments to HHS in response to Blueprint. Communications and correspondence related to suspension of claims under Medicare Part D for a credible allegation of fraud, electronic prescribing, and prior authorization under Medicare Part D contained in HR 6--The Opioid Crisis Response Act of 2018.
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2018 · third_quarter · 3A
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Met with HHS officials regarding the Administration Blueprint to Lower Drug Prices. Submitted comments to HHS in response to Blueprint. Communications and correspondence related to suspension of claims under Medicare Part D for a credible allegation of fraud, electronic prescribing, and prior authorization under Medicare Part D contained in HR 6--The Opioid Crisis Response Act of 2018.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2018 · third_quarter · RA
Issues related to Medicare Part D, opioids, Medicare Part B, value-based contracting, payment for pharmacist services, biosimilars, FDA issues, drug pricing
Issues related to Medicare Part D, opioids, Medicare Part B, value-based contracting, payment for pharmacist services, biosimilars, FDA issues, drug pricing
Issues related to Medicare Part D, opioids, Medicare Part B, value-based contracting, payment for pharmacist services, biosimilars, FDA issues, drug pricing
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2018 · third_quarter · Q3
Met with HHS officials regarding the Administration Blueprint to Lower Drug Prices. Submitted comments to HHS in response to Blueprint. Communications and correspondence related to suspension of claims under Medicare Part D for a credible allegation of fraud, electronic prescribing, and prior authorization under Medicare Part D contained in HR 6--The Opioid Crisis Response Act of 2018.
Sent a letter in support of S. 974, the CREATES Act to the full Senate and communicated in regard to the bill. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2018 · second_quarter · 2A
Submitted letter to the House Energy and Commerce Committee for the record in support of H.R. 4841 concerning standardizing electronic prior authorization for Medicare. Also sent a letter to Rep. Schweikert in support of H.R. 4841. Also sent a letter of support for H.R. 3528 for the House Energy and Commerce Committee record. H.R. 3528 provides for the e-prescribing of prescription drugs for controlled substances under Medicare Part D program. Participated in discussions on the need to address fraud, waste and abuse in the Medicare Part D program.
Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee. Dissemination of information in support of H.R. 2026 - Pharmaceutical Information Exchange Act.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2018 · second_quarter · Q2
Submitted a letter to House Energy and Commerce Committee Chair and Ranking Member in support of H.R. 3545 - Overdose Prevention and Patient Safety Act. Also sent a letter for the House Energy and Commerce Committee record in support of H.R. 4275 which directs the Secretary of HHS to develop and disseminate materials, giving pharmacists the understanding and ability to decline to fill controlled substances prescriptions that are fraudulent, forged or appear to be for abuse or diversion. Sent a letter in support of S. 974, the CREATES Act to the Chairman and Ranking Member of the Senate Judiciary Committee.
Submitted letter to the House Energy and Commerce Committee for the record in support of H.R. 4841 concerning standardizing electronic prior authorization for Medicare. Also sent a letter to Rep. Schweikert in support of H.R. 4841. Also sent a letter of support for H.R. 3528 for the House Energy and Commerce Committee record. H.R. 3528 provides for the e-prescribing of prescription drugs for controlled substances under Medicare Part D program.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2018 · first_quarter · Q1
Submitted comments to CMS on Medicare Advantage and Medicare Part D Rule, joined other stakeholders in letter HHS OIG in support of a safe harbor provision for that would encourage development of value-based contracts for the Medicare and Medicaid populations,submitted comments to CMS on the 2019 draft Call letter and submitted letter to Rep. Schweikert in support of H.R. 4148 concerning standardizing electronic prior authorization for Medicare beneficiaries.
Joined other stakeholders in a letter to Reps. Mullin and Blumenauer of support for H.R. 3545 - Overdose Prevention and Patient Safety Act, also sent a letter of support of H.R. 3545 to House Energy and Commerce Committee in support of H.R.3545 , Joined other stakeholders in letter to Senate and House leadership in support of the CREATES Act (H.R.2212 and S. 974) Delivered remarks at FDA Opioid Policy Steering Committee on ways to address the opioid epidemic, dissemination of pharmacoeconomic information,submitted letter to House Energy and Commerce Committee in support of H.R. 2026 Pharmaceutical Information Exchange Act and submitted a letter to AHRQ in response to a request for information regarding patient reported outcomes measures.
ACADEMY OF MANAGED CARE PHARMACY via ACADEMY OF MANAGED CARE PHARMACY
2017 · fourth_quarter · Q4
Submitted comments to CMMI on recommendations to transform Medicare and Medicaid Programs
Joint letter with other pharmacy associations submitted for the record in the House Energy and Commerce committee hearing on opioids in support of pharmacists being eligible for DATA waivers to provide Medication Assisted Therapy, Comments submitted to HHS Notice of Benefit and payment parameters for 2019;Comments submitted to FDA on direct to consumer advertising, Comments submitted to FDA on potential areas of focus for the opioid policy steering committee, comments submitted to the FTC on solutions and strategies to improve generic competition in the marketplace, comments submitted in response to a request for information from the House of Representatives Diabetes Caucus for information on value based contracting, dissemination of pharmaeconomic information, and H.R. 2026 Pharmaceutical Information Exchange Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE